

BCG-induced cytokine release in bladder cancer cells is regulated by Ca²⁺ signaling

Cristián Ibarra¹, Marie Karlsson¹, Simone Codeluppi^{1,2}, Manuel Varas-Godoy^{1,3}, Songbai Zhang¹, Lauri Louhivuori¹, Sara Mangsbo⁴, Arad Hosseini⁵, Navid Soltani¹, Rahim Kaba¹, T. Kalle Lundgren¹, Abolfazl Hosseini⁵, Nobuyuki Tanaka^{1,6}, Mototsugu Oya⁶, Peter Wiklund⁵, Ayako Miyakawa^{1,5} and Per Uhlén^{1,7}

1 Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden

2 Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden

3 Centro de Investigacion Biomedica, Faculty of Medicine, Universidad de los Andes, Santiago, Chile

4 Department of Pharmaceutical Biosciences, Science for Life Laboratory, Uppsala University, Sweden

5 Department of Molecular Medicine and Surgery, Karolinska University Hospital, Stockholm, Sweden

6 Department of Urology, Keio University School of Medicine, Tokyo, Japan

7 Keio University Graduate School of Medicine, Tokyo, Japan

Keywords

BCG; calcium signaling; TLR4; urinary bladder cancer

Correspondence

A. Miyakawa and P. Uhlén, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, SE-171 77 Stockholm, Sweden

Fax: +46 8 341 960

Tel: +46 8 524 87677

E-mails: ayako.miyakawa@ki.se (AM) or per.uhlen@ki.se (PU)

(Received 9 May 2018, revised 11 October 2018, accepted 14 October 2018, available online 13 December 2018)

doi:10.1002/1878-0261.12397

Bacillus Calmette–Guérin (BCG) is widely used in the clinic to effectively treat superficial urinary bladder cancer. However, a significant proportion of patients who fail to respond to BCG risk cystectomy or death. Though more than 3 million cancer treatments with BCG occur annually, surprisingly little is known about the initial signaling cascades activated by BCG. Here, we report that BCG induces a rapid intracellular Ca²⁺ (calcium ion) signal in bladder cancer cells that is essential for activating the transcription factor nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) and for synthesizing and secreting proinflammatory cytokines, including interleukin 8 (IL-8). A similar Ca²⁺ response was observed when cells were exposed to the supernatant of BCG. Studying cellular molecular mechanisms involved in the BCG signaling event, we found pivotal roles for phospholipase C and the Toll-like receptor 4. Further assessment revealed that this signaling pathway induces synthesis of IL-8, whereas exocytosis appeared to be controlled by global Ca²⁺ signaling. These results shed new light on the molecular mechanisms underlying BCG treatment of bladder cancer, which can help in improving therapeutic efficacy and reducing adverse side effects.

1. Introduction

Bacillus Calmette–Guérin (BCG), an attenuated strain of *Mycobacterium bovis*, is arguably the most effective therapy for high-risk non-muscle-invasive urinary

bladder cancer, although it was originally developed with the intention to produce a vaccine against tuberculosis (Kassouf and Kamat, 2004; Liu *et al.*, 2009; Morales *et al.*, 1976). Bladder cancer is the fourth most commonly diagnosed cancer in men and tenth

Abbreviations

bBCGsn, boiled BCGsn; BCG, Bacillus Calmette–Guérin; BCGsn, Supernatant of BCG; Ca²⁺, calcium ion; ER, endoplasmic reticulum; fBCGsn, frozen BCGsn; GPCR, G protein-coupled receptor; IL, interleukin; InsP₃, inositol 1,4,5-trisphosphate; InsP₃R, inositol 1,4,5-trisphosphate receptor; MSD, Meso Scale Discovery; NF-κB, nuclear factor kappa-light-chain-enhancer of activated B cells; PI3K, phosphatidylinositol 3-kinase; PLC, phospholipase C; ppBCGsn, protein-precipitated BCGsn; qRT-PCR, quantitative RT-PCR; TLR4, toll-like receptor 4.

most common cancer in women in the United States (Siegel *et al.*, 2017). Approximately 75% of bladder cancers do not invade the smooth muscle (Kaufman *et al.*, 2009; Simons *et al.*, 2008) and are considered non-muscle-invasive bladder cancers. The standard treatment for non-muscle-invasive bladder cancer is transurethral resection of the bladder tumor, followed by intravesical therapy with BCG (Chang *et al.*, 2016). However, a significant proportion of patients fail to respond to BCG therapy; their tumors are refractory or relapse and may become invasive or metastatic (Kaufman *et al.*, 2009).

Since the first report of intravesical use of BCG, there have been strong efforts to understand the pharmacology and toxicology of this treatment, which have hitherto been elusive. BCG is a mixture containing viable microorganisms, bacterial fragments, intracellular content, and soluble secreted compounds. It is currently accepted that the antitumor activity of BCG is derived by a local non-specific immunological boost that recruits immunocompetent cells (Redelman-Sidi *et al.*, 2014). Several studies report that BCG instillation results in a significant cell-mediated response in the bladder, characterized by secretion of cytokines and recruitment of immune cells (Redelman-Sidi *et al.*, 2014). However, the exact sequence of events from the BCG instillation to tumor eradication has been only partially addressed, which has limited the development of new BCG derivatives with enhanced clinical efficacy and fewer adverse side effects.

Calcium (Ca²⁺) signaling has been reported to regulate cytokine release and tumor growth (Berridge *et al.*, 1998; Monteith *et al.*, 2017; Roderick and Cook, 2008; Uhlen *et al.*, 2000). Through the concert of actions between Ca²⁺ channels and pumps, intracellular signals can be shaped in infinite ways (Uhlen and Fritz, 2010). Release of Ca²⁺ from intracellular endoplasmic reticulum (ER) Ca²⁺ stores mainly occurs through inositol 1,4,5-trisphosphate (InsP₃) receptors (InsP₃Rs), which are activated when phosphatidylinositol 4,5-bisphosphate is cleaved by phospholipase C (PLC) into InsP₃ and diacylglycerol. The subsequent elevation of the cytosolic Ca²⁺ concentration can activate downstream effectors that control numerous biological processes in cells (Mengel *et al.*, 2010).

2. Methods

2.1. Cell cultures

Human bladder tumors were collected from patients undergoing transurethral resection in the Urology Unit of Karolinska University Hospital. Primary cell

cultures were prepared as previously described (Rahman *et al.*, 1987). Briefly, tissue was finely minced, enzymatically digested, pipetted to disperse clumps, washed in phosphate-buffered saline, and cultured in a specialized medium. All experiments were ethically approved (Dnr 2011/421-31/1), and written consent was obtained from all participants. The study methodologies conformed to the standards set by the Declaration of Helsinki.

The urinary bladder cancer cell lines T24 (human), RT4 (human), and MB49 (mouse) were purchased from ATCC (American Type Culture Collection, Manassas, VA, USA) and were occasionally tested for mycoplasma (last tested in 2015). Cells were propagated according to their instructions, and all experiments were performed using cells between passage numbers 3 and 20.

2.2. BCG treatment

Bacillus Calmette–Guérin (2×10^8 – 3×10^9 cfu, Medac, Chicago, IL, USA) RIVM-derived strain (1173-P2) was resuspended in 5 mL of the cell line-specific culture medium. The BCG mixture was then diluted 10 times to the final concentration of 4×10^6 – 6×10^7 cfu·mL⁻¹ and treated to the cells for the indicated time period. To fractionate the BCG, it was centrifuged at 3000 *g* for 30 min to separate a BCG pellet and BCG supernatant (BCGsn). The BCGsn was frozen (fBCGsn) at -20 °C overnight, boiled (bBCGsn) at 100 °C for 1 h, or treated with acetone to precipitate protein (ppBCGsn). Proteins within ppBCGsn were separated into mass fractions: > 100, > 50, > 30, > 10, and > 3 kDa (Amicon tubes, Millipore, St Charles, MO, USA).

2.3. Reagents

The following reagents were used: cyclopiazonic acid (CPA, 50 μM, Tocris Bioscience, Bristol, UK); 2-aminoethoxydiphenylborane (2APB, 100 μM, Tocris); U73122 (2–4 μM, Tocris, Abingdon, UK); U73343 (2–4 μM, Tocris); Edelfosine (ET-18-OCH₃, 2–4 μM, Tocris); Wortmannin (1 μM, Tocris); Pertussis toxin (PTX, 1 μg·mL⁻¹, Tocris); and 6-(phenylsulfonyl)tetrazolo[1,5-b]pyridazine (Ro 106-9920, 0.01–100 μM, Tocris), Xestospongine D (Xesto, 5 μM, Tocris).

2.4. Calcium imaging

Cells were loaded with the Ca²⁺-sensitive fluorescence indicator Fluo-3/AM (5 μM, Invitrogen, Carlsbad, CA, USA) in Krebs-Ringer solution (119 mM NaCl, 2.5 mM KCl, 2.5 mM CaCl₂, 1.3 mM MgCl₂, 1.0 mM

NaH₂PO₄, 20.0 mM HEPES (pH 7.4), and 11.0 mM dextrose) at 37 °C with 5% CO₂ for 30 min prior to experiments. The Ca²⁺ imaging was conducted at 37 °C in a heat-controlled chamber (QE-1, Warner Instruments, New Haven, CT, USA) with a confocal microscope Zeiss LSM510NLO META (Carl Zeiss, Jena, Germany) equipped with a 20x/0.8NA dipping lens (Carl Zeiss). Excitation was set at 488 nm and emission was detected at 510 nm. The sampling frequency was set to 0.1 Hz. CARL ZEISS software (Carl Zeiss) was used to analyze the acquired images. Experiments were performed in a Krebs-Ringer buffer and all drugs were bath-applied.

2.5. Cytokine measurements

The level of secreted cytokines in response to BCG was measured with a Meso Scale Discovery (MSD) MULTI-SPOT Assay System (Meso Scale Discovery, Rockville, MD, USA). Cytokines were analyzed in the supernatants of human primary bladder cancer cultures by the Human ProInflammatory 9-Plex Ultra-Sensitive Kit and in mouse MB49 cells by the Mouse ProInflammatory 9-Plex Ultra-Sensitive Kit, following instructions from the manufacturer. Controls for standard curves were included with each plate. Data are presented as the means ± standard error of the mean of a minimum of four experiments.

2.6. Small interfering RNA

siRNA against PLCβ3 and PLCγ (Dharmacon, Lafayette, CO, USA) were used to knock down proteins. T24 cells were seeded in 25-mm plates to 60% confluency, and siRNA (100 μM) was transfected into cells with Lipofectamine 2000 (Invitrogen) in Opti-MEM (Invitrogen), according to the manufacturers' instructions. The knockdown efficiency of siRNA was confirmed by western blotting (Fig. S1A,B).

2.7. Western blotting

Cells were lysed in a modified RIPA buffer for 20 min at 4 °C, and equal amounts of protein were separated on a 10% sodium dodecyl sulfate gel electrophoresis, followed by transfer to a PVDF membrane. The membranes were blocked in 5% milk or bovine serum albumin in TRIS-buffered saline solution with 0.5% Tween-20 for 1 h before incubation with primary antibodies (PLCβ3, 1 : 1000; PLCγ, 1 : 1000; β-actin, 1 : 1000, Abcam, Cambridge, UK) overnight at 4 °C and further incubation with secondary antibodies (1 : 5000) for 1 h. Bands were detected with a chemiluminescence kit (Amersham

Biosciences, GE Healthcare UK Limited, Bucks, UK) and an imaging system (Bio-Rad, Hercules, CA, USA).

2.8. Luciferase reporter assays

The activity of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) was determined with a NF-κB-firefly-luciferase reporter and CMV-Renilla-luciferase reporter constructs (Promega, Madison, WI, USA). MB49 cells were seeded at 1–2 × 10⁴ cells per well in 96-well culture plates. On the following day, cells were co-transfected with a firefly-luciferase reporter construct with an interleukin 8 (IL-8) promoter (or five copies of NF-κB response element; 0.1 μg-well⁻¹) and pCMV-Renilla-luciferase (0.005 μg-well⁻¹) using Lipofectamine and PLUS reagents, according to the manufacturer's protocol (Invitrogen). Three hours after transfection, the medium was removed and replaced with complete Dulbecco's modified Eagle's medium for 24 h. The cells were preincubated with inhibitors for 24 h and then stimulated with BCG for 18 h. Then, cells were washed once with phosphate-buffered saline and lysed in 25 μL Tropix lysis solution per well. Luciferase activity was determined with a Dual Luciferase Reporter Gene Assay (Promega) and a Wallac Victor² 1420 Multilabel Counter according to the manufacturer's instructions (Wallac, Gaithersburg, MD, USA). Renilla-luciferase activity was analyzed to verify the reproducibility between quadruplicate transfections in all experiments.

2.9. Lentiviral vector production and *in vitro* transduction

Short hairpin RNA (shRNA) targeting the mouse Toll-like receptor 4 (TLR4) mRNA, and a non-related sequence (Control) were cloned into the lentiviral vector pLL3.7-mRuby (Rubinson *et al.*, 2003). The shRNA sequences were sh1TLR4: 5'-GCATAGAGG TAGTTCCTAATA -3', sh2TLR4: 5'-CTTCACTACA GAGACTTTA-3', and shControl: 5'-TTCTCCGAA CGTGTCACGT-3'. Lentivirus was produced by co-transfecting the packaging vector pΔ8.91 and the envelope vector pCMV-VSVg with the pLL3.7.mRuby2 into HEK293FT cells (Invitrogen). The resulting supernatant was harvested after 60 h, concentrated by ultracentrifugation (95 min at 103.864 g in a Beckman JS-24.38 rotor) and resuspended in 100 μL of RPMI 1640 medium. MB49 cells were transduced and selected by cell sorting (BD FACS Aria II cell sorter) targeting the mRuby reporter. Downregulation of TLR4 was confirmed by quantitative RT-PCR (qRT-PCR; Fig. S1C). Briefly, total RNA from transduced

MB49 cells was isolated with the RNeasy Mini Kit (QIAGEN, Hilden, Germany) and reverse transcribed with the Superscript II Kit (Invitrogen). qRT-PCR assays were performed with the SYBR[®] green PCR master mix (Applied Biosystems, Foster City, CA, USA) in an ABI PRISM 7900HT sequence detection system (Applied Biosystems). The expression of the target mRNA was normalized to glyceraldehyde 3-phosphate dehydrogenase (GAPDH). The primers used were mouse TLR4 forward: 5'-CACTGTTCTTCTCCTGCCTGAC-3', mouse TLR4 reverse: 5'-CCTGGGGAAAACCTCTGGATAG-3', mouse GAPDH forward: 5'-TGACCTCAACTACATGGTCTACA-3', and mouse GAPDH reverse: 5'-CTTCCCATCTCGGCCTTG-3'. sh2TLR4 was selected for further experiments.

2.10. Statistical analysis

The Ca²⁺ recording data were normalized and cells were considered responsive to a treatment if the mean fluorescence was increased by at least 50% over the baseline. All the data are presented as the means ± SEM. Unless otherwise stated, at least three biological repeats were performed for all of the cell culture experiment. Groups were compared by Student's two-tailed unpaired *t*-test or one-way ANOVA, with a *P*-value < 0.05 as the limit for statistical significance.

3. Results

3.1. BCG elevates the cytosolic Ca²⁺ concentration

To test the influence of BCG on Ca²⁺ homeostasis in urinary bladder cancer cells, we collected tumor samples from patients treated with transurethral resection. We prepared primary cultures of human bladder cancer cells and loaded them with Fluo-3/AM to monitor the cytosolic Ca²⁺ concentration with time-lapse fluorescence microscopy. First, the basal Ca²⁺ level was recorded for ~5 min, and then, a clinically relevant preparation of BCG (4×10^6 – 6×10^7 cfu·mL⁻¹) was applied to the cells. A rapid cytosolic Ca²⁺ increase was observed when primary bladder cancer cells were exposed to BCG (Fig. 1A). Next, we assayed the Ca²⁺ response to BCG in T24 cells, a human cell line derived from poorly differentiated (grade III) bladder carcinoma (Bubenik *et al.*, 1973), RT4 cells, a human cell line derived from a grade I urothelial carcinoma (Franks and Rigby, 1975), and MB49 cells, a murine model of bladder cancer (Summerhayes and Franks, 1979). BCG triggered Ca²⁺ responses in all these cell types (Figs 1B,

S2A,B, and Movie S1). Interestingly, the Ca²⁺ responses induced by BCG showed oscillatory behaviors. To determine whether the rise in cytosolic Ca²⁺ was due to influx from the extracellular milieu, we repeated the experiment in a Ca²⁺-free medium. Eliminating extracellular Ca²⁺ had no apparent effect on the BCG-induced Ca²⁺ response (Fig. 1C,D), suggesting that the major Ca²⁺ source was intracellular stores.

The intracellular Ca²⁺ signaling pathway triggered by BCG was further scrutinized in human T24 cells, of which $76.2 \pm 4.4\%$ ($n = 2231$, $N = 21$) showed a Ca²⁺ response when exposed to BCG (Fig. 1E). First, internal ER Ca²⁺ stores were depleted by blocking the SERCA pump with CPA, which abolished the BCG-induced Ca²⁺ signal (Figs 1E and S3A). Then, we




Fig. 1. BCG evokes intracellular Ca²⁺ signaling in bladder cancer cells. Primary human bladder cancer cells (A) and human T24 cells (B) exposed to BCG (4×10^6 – 6×10^7 cfu·mL⁻¹) in a Ca²⁺-containing buffer exhibit Ca²⁺ signaling. Primary human bladder cancer cells (C) and human T24 cells (D) exposed to BCG (4×10^6 – 6×10^7 cfu·mL⁻¹) in a Ca²⁺-free buffer also exhibit Ca²⁺ signaling. (E) The number of human T24 cells responding to BCG with Ca²⁺ signaling was significantly reduced by the inhibitors CPA, 2APB, U73122, ET-18-OCH3 (ET-18), and PTX, whereas wortmannin failed to significantly reduce the number of active cells. Results are means ± SEM of measurements from at least three separate cell cultures. **P* < 0.05, ***P* < 0.01, ****P* < 0.001 (Student's *t*-test).




Fig. 2. BCG triggers cytokine release in bladder cancer cells. Primary human bladder cancer cells derived from one male tumor (A) and one female tumor (B) or mouse MB49 cells (C) exposed to BCG (4×10^6 – 6×10^7 cfu·mL⁻¹) secrete multiple cytokines, as compared to a control group. Results are means \pm SEM of measurements from four separate cell cultures. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$ (Student's *t*-test)

inhibited InsP₃Rs with 2APB or Xestospongin D, which abolished the response (Figs 1E and S3B,C). Additionally, blocking PLC with U73122 or ET-18-OCH₃ completely eliminated the BCG-induced response (Figs 1E and S3D). U73343, the inactive analog of U73122, had no effect (Figs 1E and S3E).

We next applied RNA silencing (siRNA) to pinpoint which isoform of PLC was involved in the signaling event. siRNA-based knockdown of PLCβ₃ inhibited the BCG-induced Ca²⁺ response (Fig. S3F), whereas siRNA knockdown of PLCγ did not (Fig. S3G). Since G protein-coupled receptors (GPCRs) and receptor tyrosine kinases interact with PLC, we then tested whether they played a role in BCG-induced Ca²⁺ signaling by treating cells with PTX and the phosphatidylinositol 3-kinase (PI3K) inhibitor wortmannin. PTX abolished the Ca²⁺ response (Figs 1E and S3H), while wortmannin did not (Figs 1E and S3I). The wortmannin experiment demonstrated that PI3K signaling was not required for the Ca²⁺ mobilization. Together, these data suggest that BCG triggers an intracellular Ca²⁺ response that is mediated by the release of Ca²⁺ from internal ER stores through a mechanism dependent on PLCβ₃ and GPCRs.

3.2. BCG-induced cytokine release is Ca²⁺ dependent

We next sought out to test whether BCG-induced cytokine release (Redelman-Sidi *et al.*, 2014) in bladder cancer cells was dependent on Ca²⁺ signaling. We decided to carry out these experiments on primary cultures of bladder cancer cells and MB49 cells, which is a widely used murine model of bladder cancer that is also sensitive to immunotherapy (Gunther *et al.*, 1999; Kobayashi *et al.*, 2015). Culturing primary human bladder cancer cells from a male tumor and a female tumor, we found that BCG induces release of a wide range of cytokines (Fig. 2A,B). In particular, IL-6 and IL-8 were released at significant levels in primary human bladder cancer cells as well as in mouse MB49 cells (Fig. 2C). BCG also induced a strong release of IFN-γ, TNF-α, IL-1β, IL-10, and IL-12p70 in human bladder cancer cells. To determine whether the cytokine production was dependent on Ca²⁺ signaling, we measured IL-8 release in MB49 cells pretreated with the inhibitors 2APB or U73122. Both drugs significantly hampered the BCG-induced secretion of IL-8 (Fig. 3A). Since NF-κB is known to be regulated by Ca²⁺ signaling (Smedler and Uhlen, 2014) and to modulate IL-8 (Karin *et al.*, 2002), we then examined whether NF-κB activation was induced by BCG. We determined that BCG induced a time-dependent




Fig. 3. BCG activates NF- κ B and IL-8. (A) BCG-stimulated IL-8 secretion is reduced when Ca²⁺ signaling is inhibited by 2APB or U73122 (U73). (B) NF- κ B reporter gene assay shows that NF- κ B is fully activated after 6 h of BCG treatment. (C) NF- κ B reporter gene assay shows that the NF- κ B activation is reduced when Ca²⁺ signaling is inhibited by 2APB or U73122 (U73). (D) BCG-stimulated IL-8 transcription is blocked when Ca²⁺ signaling is inhibited by 2APB. (E) BCG-stimulated IL-8 secretion levels are NF- κ B dependent as the inhibitor Ro106-9920 hampers IL-8 secretion in a dose-dependent manner. Results are means \pm SEM of measurements from at least three separate cell cultures. * P < 0.05, ** P < 0.01, *** P < 0.001 (one-way ANOVA)

transcriptional activation of NF- κ B that leveled off after 6 h (Fig. 3B). This activation was indeed Ca²⁺ dependent, as 2APB and U73122 were able to hinder NF- κ B transcription induced by BCG (Fig. 3C).

Next, we analyzed the IL-8 promoter activity. Inhibiting the intracellular Ca²⁺ release with 2APB abrogated IL-8 transcription induced by BCG (Fig. 3D). To test whether the secretion of IL-8 was dependent on NF- κ B activation, we gradually inhibited NF- κ B by varying the concentration of the NF- κ B inhibitor Ro106-9920 together with a constant maximum dose of BCG. This experiment revealed a positive correlation between the NF- κ B activation and IL-8 secretion (Fig. 3E).

These findings indicate that BCG-evoked cytokine secretion is dependent on Ca²⁺ signaling and subsequent NF- κ B transcription.

3.3. The supernatant of BCG and TLR4 are activating IL-8

The BCG mixture used in the clinic contains viable microorganisms, bacterial fragments, intracellular content, and soluble secreted compounds. We decided to

screen for key bioactive compounds within the BCG mixture responsible for triggering the Ca²⁺ signaling response. First, we prepared a BCGsn. To our surprise, exposing cells to the BCGsn resulted in a similar Ca²⁺ response to that observed with the entire BCG mixture (Fig. 4A). In contrast, exposing cells to the BCG pellet failed to elicit Ca²⁺ signaling (Fig. 4B). To test whether the response required enzymatic activity we prepared fBCGsn and to test whether it was protein dependent, we prepared bBCGsn and protein-precipitated BCGsn (ppBCGsn). All three preparations were found to evoke Ca²⁺ responses in bladder cancer cells (Fig. 4C,E). Next, we fractionated ppBCGsn according to the following molecular weights: > 100, > 50, > 30, > 10, and > 3 kDa. All fractions except > 100 kDa triggered Ca²⁺ responses (Fig. 4F), suggesting that the bioactive compound(s) triggering the Ca²⁺ response was lighter than 100 kDa. Indeed, when performing a polyacrylamide gel electrophoresis of the different BCG fractions, a majority of the bands detected were lighter than 100 kDa (Fig. S4).

We then tested whether the various BCG fractions could also activate IL-8. Treating cells with BCGsn, fBCGsn, bBCGsn, or ppBCGsn showed a similar IL-8 response as treating with whole BCG (Fig. 4G). When exposing cells to a series of different BCG concentrations, we found that the IL-8 secretion stimulated by BCG was dose dependent (Fig. 4H). Next, we investigated whether TLR4 was involved the release of IL-8. We used lentivirus encoding shRNA against TLR4 (shTLR4), as well as scramble shRNA as a control (shControl). Infecting cells with shTLR4 and exposing them to BCG completely abolished the IL-8 promoter activity (Fig. 4I). In contrast, measuring IL-8 secretion under the same conditions demonstrated no effect of TLR4 knockdown (Fig. 4J). Together, these observations indicate that bioactive compounds within the BCGsn are evoking Ca²⁺ signaling and that TLR4 is controlling the synthesis, not the exocytosis, of IL-8.

4. Discussion

Despite the frequent clinical usage of BCG to eradicate bladder cancer, little is known about its mechanism of action. Nevertheless, several studies report that BCG causes a local immune response reaction in the bladder (de Boer *et al.*, 1997; Jackson *et al.*, 1995; Redelman-Sidi *et al.*, 2014; Thalmann *et al.*, 2000). BCG induces cancer cells in the bladder to secrete cytokines and chemokines, which attract cells of the immune system (Horinaga *et al.*, 2005; Kamat *et al.*, 2009; Liu *et al.*, 2009). The cancer cells are subsequently killed by cytotoxic cells recruited to the site of




Fig. 4. The BCGsn and TLR4 are key for BCG-induced Ca²⁺ signaling. Assessment of Ca²⁺ signaling in mouse MB49 cells exposed to BCG preparations BCGsn (A), BCG pellet (B), fBCGsn (C), bBCGsn (D), ppBCGsn (E), or various weight fractions (F). (G) The BCG preparations that triggers Ca²⁺ signaling also stimulate IL-8 secretion. (H) BCG at dilutions of 1/16, 1/8, 1/4, 1/2, and 1/1 activate IL-8 in a dose-dependent manner. TLR4 knockdown with shRNA (shTLR4) abolishes BCG-induced IL-8 transcription (I) but not IL-8 secretion (J), compared to scramble shRNA controls (shControl). Results are means ± SEM of measurements from at least three separate cell cultures. **P* < 0.05, ***P* < 0.01, ****P* < 0.001 (Student's *t*-test).

the inflammatory response. IL-6 and IL-8 rapidly appear in the urine of BCG-instilled patients and are believed to initiate the host immune response (Kamat *et al.*, 2016). In this study, we shed new light on the signaling mechanisms involved in the eradication of bladder cancer following BCG therapy.

The BCG mixture injected into the bladder of cancer patients contains a myriad of compounds, including fragments of bacteria and even semi-live bacteria. Early publications report that one immunostimulatory compound in BCG is non-methylated CG-rich DNA fragments that can induce a potent immune activation (Yamamoto *et al.*, 1992a,b). However, most likely several compounds within the BCG mixture are involved in the overall response. Interestingly, our data show that the BCG supernatant sBCG can stimulate cytosolic Ca²⁺ signaling and cytokine release. We identified TLR4 as an essential receptor for BCG-induced Ca²⁺ signaling. Previously, expression of both TLR4 and TLR9 has been reported in human bladder cancer cells (Olbert *et al.*, 2015). Our data show that inhibiting Ca²⁺ signaling with 2APB or knocking down TLR4 with shRNA completely blocks IL-8 promoter activity. Surprisingly, knocking down TLR4 had no effect on IL-8 secretion, whereas inhibiting Ca²⁺ signaling partly reduced secretion. This indicates that global

Ca²⁺ signaling regulates exocytosis. However, more information about the various compounds within BCG and their actions on cells is necessary to fully understand the overall cellular response. We speculate that bioactive compounds within the BCG mixture can be counterproductive. Identifying such compounds can help reduce adverse side effects of BCG therapy as well as decrease the risk of cancer relapse or progression to more invasive disease.

Our data show that pertussis toxin and PLC can inhibit BCG-induced Ca²⁺ signaling. It has been demonstrated that mice with orthotopic bladder tumors that receive a recombinant BCG expressing pertussis toxin have less tumor growth than animals receiving ordinary BCG (Chade *et al.*, 2008). Interestingly, a new TLR transduction mechanism that involves Ca²⁺ signaling was recently reported (Shintani *et al.*, 2013, 2014). TLR9 stimulation reduced ER Ca²⁺-ATPase activity, modulating Ca²⁺ handling between the ER and mitochondria, which resulted in decreased mitochondrial ATP levels and activation of protective cellular machineries. It is possible that when treating bladder cancer patients with BCG, parallel protective machineries are activated that could hinder the cancer eradication process and explain why some patients fail to respond to BCG. One such parallel process might be the

secretion of IL-8, which can act as a tumorigenic and pro-angiogenic factor, driving tumor growth (Singh and Lokeshwar, 2011; Xie, 2001; Zhao *et al.*, 2017).

A major challenge with the BCG therapy is its severe side effects, such as BCG sepsis, immunosuppression, hematuria, active urinary tract infection, and mild cystitis (Kresowik and Griffith, 2009). Another disadvantage with the therapy is that a significant proportion (~40%) are refractory cancers that fail to respond to the BCG therapy (O'Donnell and Boehle, 2006; Packiam *et al.*, 2017). Why some patients fail to respond is largely unknown. Based on our results, we speculate that concerted actions of multiple signaling pathways define the efficiency of the BCG therapy. BCG triggers a long chain of events that critically regulates each other. Patients with a malfunction in this cascade of events may have refractory cancer. We here present a much more comprehensive picture of the initial signaling event triggered by BCG, containing multiple interlinked signaling pathways. At the molecular level, it appears that bioactive compounds present in the BCGs interact with TLR4 to trigger a Ca²⁺ response, which subsequently activates NF- κ B.

5. Conclusion

Our work opens the door to more extensive studies of the mechanism of action of BCG therapy for bladder cancer. By better understanding the BCG-mediated signaling cascades, we will be better able to design more efficient therapeutic strategies with less adverse side effects when treating patients with bladder cancer.

Acknowledgements

The authors would like to thank Dr Benedict Chambers for helpful discussions and Nasrin Bavand, Alessandra Nanni, and Johnny Söderlund for technical and administrative assistance. This work was supported by the Swedish Research Council (grants 2009-3364, 2013-3189, and 2017-00815 to PU), the Swedish Strategic Foundation (MultiBIO 2010 to PU), the Swedish Cancer Society (grant CAN 2013-802 and CAN 2016-801 to PU), Linnaeus Center in Developmental Biology for Regenerative Medicine (DBRM), the Knut and Alice Wallenberg Foundation (grants CLICK and Research Fellow to PU), the Karolinska Institutet's KID doctoral program (to MK), Åke Wiberg's Foundation (to PU), Magnus Bergvall's Foundation (to PU), Fredrik and Ingrid Thuring's Foundation (to PU), Sigrid Jusélius Foundation (to LL), Hillevi Fries' Foundation (to AM), the Olle

Engkvist Foundation (to PU), and the Swedish Society for Medical Research (to PU, SC and TKL).

Ethics approval and consent to participate

All experiments were ethically approved by the Karolinska University Hospital Ethical Committee (Dnr 2011/421-31/1) and all patients were informed.

Conflict of interest

The authors declare no conflict of interest.

Authors' contributions

CI, MK, SC, and MVG designed research, performed research, and analyzed data. SZ, LL, NS, RK, and TKL performed research. ArH and AbH collected the tumor samples and clinical information. AbH, PW, SM, and MO advised the design of research. CI, MVG, SC, SM, AM, and PU prepared the manuscript. AM and PU designed the project. All authors read and approved the final manuscript.

References

- Berridge MJ, Bootman MD and Lipp P (1998) Calcium—a life and death signal. *Nature* **395**, 645–648.
- Bubenik J, Baresova M, Viklicky V, Jakoubkova J, Sainerova H and Donner J (1973) Established cell line of urinary bladder carcinoma (T24) containing tumour-specific antigen. *Int J Cancer* **11**, 765–773.
- Chade DC, Borra RC, Nascimento IP, Villanova FE, Leite LC, Andrade E, Srougi M, Ramos KL and Andrade PM (2008) Immunomodulatory effects of recombinant BCG expressing pertussis toxin on TNF-alpha and IL-10 in a bladder cancer model. *J Exp Clin Cancer Res* **27**, 78.
- Chang SS, Boorjian SA, Chou R, Clark PE, Daneshmand S, Konety BR, Pruthi R, Quale DZ, Ritch CR, Seigne JD *et al.* (2016) Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO guideline. *J Urol* **196**, 1021–1029.
- de Boer EC, Somogyi L, de Ruiter GJ, de Reijke TM, Kurth KH and Schamhart DH (1997) Role of interleukin-8 in onset of the immune response in intravesical BCG therapy for superficial bladder cancer. *Urol Res* **25**, 31–34.
- Franks LM and Rigby C (1975) Letter: HeLa cells and RT4 cells. *Science* **188**, 168.
- Gunther JH, Jurczok A, Wulf T, Brandau S, Deinert I, Jocham D and Bohle A (1999) Optimizing syngeneic

- orthotopic murine bladder cancer (MB49). *Cancer Res* **59**, 2834–2837.
- Horinaga M, Harsch KM, Fukuyama R, Heston W and Larchian W (2005) Intravesical interleukin-12 gene therapy in an orthotopic bladder cancer model. *Urology* **66**, 461–466.
- Jackson AM, Alexandroff AB, Kelly RW, Skibinska A, Esuvaranathan K, Prescott S, Chisholm GD and James K (1995) Changes in urinary cytokines and soluble intercellular adhesion molecule-1 (ICAM-1) in bladder cancer patients after Bacillus Calmette-Guerin (BCG) immunotherapy. *Clin Exp Immunol* **99**, 369–375.
- Kamat AM, Briggman J, Urbauer DL, Svatek R, Noguera Gonzalez GM, Anderson R, Grossman HB, Prat F and Dinney CP (2016) Cytokine Panel for Response to Intravesical Therapy (CyPRIT): nomogram of changes in urinary cytokine levels predicts patient response to bacillus calmette-guerin. *Eur Urol* **69**, 197–200.
- Kamat AM, Tharakan ST, Sung B and Aggarwal BB (2009) Curcumin potentiates the antitumor effects of Bacillus Calmette-Guerin against bladder cancer through the downregulation of NF-kappaB and upregulation of TRAIL receptors. *Cancer Res* **69**, 8958–8966.
- Karin M, Cao Y, Greten FR and Li ZW (2002) NF-kappaB in cancer: from innocent bystander to major culprit. *Nat Rev Cancer* **2**, 301–310.
- Kassouf W and Kamat AM (2004) Current state of immunotherapy for bladder cancer. *Expert Rev Anticancer Ther* **4**, 1037–1046.
- Kaufman DS, Shipley WU and Feldman AS (2009) Bladder cancer. *Lancet* **374**, 239–249.
- Kobayashi T, Owczarek TB, McKiernan JM and Abate-Shen C (2015) Modelling bladder cancer in mice: opportunities and challenges. *Nat Rev Cancer* **15**, 42–54.
- Kresowik TP and Griffith TS (2009) Bacillus Calmette-Guerin immunotherapy for urothelial carcinoma of the bladder. *Immunotherapy* **1**, 281–288.
- Liu W, O'Donnell MA, Chen X, Han R and Luo Y (2009) Recombinant bacillus Calmette-Guerin (BCG) expressing interferon-alpha 2B enhances human mononuclear cell cytotoxicity against bladder cancer cell lines *in vitro*. *Cancer Immunol Immunother* **58**, 1647–1655.
- Mengel B, Hunziker A, Pedersen L, Trusina A, Jensen MH and Krishna S (2010) Modeling oscillatory control in NF-kappaB, p53 and Wnt signaling. *Curr Opin Genet Dev* **20**, 656–664.
- Monteith GR, Prevarskaya N and Roberts-Thomson SJ (2017) The calcium-cancer signalling nexus. *Nat Rev Cancer* **17**, 367–380.
- Morales A, Eidinger D and Bruce AW (1976) Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. *J Urol* **116**, 180–183.
- O'Donnell MA and Boehle A (2006) Treatment options for BCG failures. *World J Urol* **24**, 481–487.
- Olbert PJ, Kesch C, Henrici M, Subtil FS, Honacker A, Hegele A, Hofmann R and Hanze J (2015) TLR4- and TLR9-dependent effects on cytokines, cell viability, and invasion in human bladder cancer cells. *Urol Oncol* **33**(110), e119–e127.
- Packiam VT, Johnson SC and Steinberg GD (2017) Non-muscle-invasive bladder cancer: intravesical treatments beyond Bacille Calmette-Guerin. *Cancer* **123**, 390–400.
- Rahman Z, Reedy EA and Heatfield BM (1987) Isolation and primary culture of urothelial cells from normal human bladder. *Urol Res* **15**, 315–320.
- Redelman-Sidi G, Glickman MS and Bochner BH (2014) The mechanism of action of BCG therapy for bladder cancer—a current perspective. *Nat Rev Urol* **11**, 153–162.
- Roderick HL and Cook SJ (2008) Ca²⁺ signalling checkpoints in cancer: remodelling Ca²⁺ for cancer cell proliferation and survival. *Nat Rev Cancer* **8**, 361–375.
- Rubinson DA, Dillon CP, Kwiatkowski AV, Sievers C, Yang L, Kopinja J, Rooney DL, Zhang M, Ihrig MM, McManus MT et al. (2003) A lentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interference. *Nat Genet* **33**, 401–406.
- Shintani Y, Drexler HC, Kioka H, Terracciano CM, Coppen SR, Imamura H, Akao M, Nakai J, Wheeler AP, Higo S et al. (2014) Toll-like receptor 9 protects non-immune cells from stress by modulating mitochondrial ATP synthesis through the inhibition of SERCA2. *EMBO Rep* **15**, 438–445.
- Shintani Y, Kapoor A, Kaneko M, Smolenski RT, D'Acquisto F, Coppen SR, Harada-Shoji N, Lee HJ, Thiemermann C, Takashima S et al. (2013) TLR9 mediates cellular protection by modulating energy metabolism in cardiomyocytes and neurons. *Proc Natl Acad Sci U S A* **110**, 5109–5114.
- Siegel RL, Miller KD and Jemal A (2017) Cancer statistics, 2017. *CA Cancer J Clin* **67**, 7–30.
- Simons MP, O'Donnell MA and Griffith TS (2008) Role of neutrophils in BCG immunotherapy for bladder cancer. *Urol Oncol* **26**, 341–345.
- Singh RK and Lokeshwar BL (2011) The IL-8-regulated chemokine receptor CXCR7 stimulates EGFR signaling to promote prostate cancer growth. *Cancer Res* **71**, 3268–3277.
- Smedler E and Uhlen P (2014) Frequency decoding of calcium oscillations. *Biochim Biophys Acta* **1840**, 964–969.

- Summerhayes IC and Franks LM (1979) Effects of donor age on neoplastic transformation of adult mouse bladder epithelium *in vitro*. *J Natl Cancer Inst* **62**, 1017–1023.
- Thalmann GN, Sermier A, Rentsch C, Mohrle K, Cecchini MG and Studer UE (2000) Urinary Interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guerin. *J Urol* **164**, 2129–2133.
- Uhlen P and Fritz N (2010) Biochemistry of calcium oscillations. *Biochem Biophys Res Commun* **396**, 28–32.
- Uhlen P, Laestadius A, Jahnukainen T, Soderblom T, Backhed F, Celsi G, Brismar H, Normark S, Aperia A and Richter-Dahlfors A (2000) Alpha-haemolysin of uropathogenic *E. coli* induces Ca²⁺ oscillations in renal epithelial cells. *Nature* **405**, 694–697.
- Xie K (2001) Interleukin-8 and human cancer biology. *Cytokine Growth Factor Rev* **12**, 375–391.
- Yamamoto S, Yamamoto T, Kataoka T, Kuramoto E, Yano O and Tokunaga T (1992a) Unique palindromic sequences in synthetic oligonucleotides are required to induce IFN [correction of INF] and augment IFN-mediated [correction of INF] natural killer activity. *J Immunol* **148**, 4072–4076.
- Yamamoto S, Yamamoto T, Shimada S, Kuramoto E, Yano O, Kataoka T and Tokunaga T (1992b) DNA from bacteria, but not from vertebrates, induces interferons, activates natural killer cells and inhibits tumor growth. *Microbiol Immunol* **36**, 983–997.
- Zhao Z, Wang S, Lin Y, Miao Y, Zeng Y, Nie Y, Guo P, Jiang G and Wu J (2017) Epithelial-mesenchymal transition in cancer: role of the IL-8/IL-8R axis. *Oncol Lett* **13**, 4577–4584.

Supporting information

Additional supporting information may be found online in the Supporting Information section at the end of the article.

Fig. S1. Validating knock-down efficiency of siRNA and shRNA.

Fig. S2. BCG evokes intracellular Ca²⁺ signaling in bladder cancer cells.

Fig. S3. Scrutinizing the BCG-induced Ca²⁺ signal cascade in bladder cancer cells.

Fig. S4. Screening substances in BCG. Polyacrylamide gel electrophoresis of the BCG mixture.

Movie S1. BCG-induced Ca²⁺ signaling in bladder cancer cells.